• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

GoodRx Partners with ARS to Offer Discounted neffy® for Allergy Relief

by Fred Pennic 09/26/2024 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know: 

– GoodRx, a prominent prescription savings platform in the U.S., has joined forces with ARS Pharmaceuticals to offer the lowest discounted cash price for neffy®, a revolutionary needle-free treatment for Type I allergic reactions. 

– The partnership makes neffy available for $199 at over 70,000 pharmacies across the nation, exclusively through GoodRx.

neffy: A Needle-Free Solution for Anaphylaxis

Allergies and allergic reactions affect over 100 million Americans annually, with anaphylaxis posing a serious threat.  Approved by the FDA in August, neffy is the first needle-free treatment for anaphylaxis and other Type I allergic reactions, offering an alternative to traditional auto-injectors. By delivering epinephrine nasally, neffy eliminates the need for needle injections, a major hurdle for many, especially children and adults who require epinephrine.

GoodRx: Championing Innovation and Accessibility

GoodRx is dedicated to making essential medications more accessible and affordable while promoting innovation in healthcare. The company’s partnership with ARS Pharmaceuticals highlights this commitment, ensuring that neffy is available at a lower price, breaking down barriers to anaphylaxis treatment and offering a more convenient option for millions of Americans.

“We’re thrilled about neffy’s U.S. Food and Drug Administration approval, so people with severe allergies don’t have to endure needle-injection of epinephrine, which can be fraught with anxiety and fear, and can carry a device that’s small and effective. Through our partnership with GoodRx, we can offer our innovation in retail pharmacies along with patient programs to support its affordability,” said Richard Lowenthal, Co-Founder, President, and Chief Executive Officer of ARS Pharmaceuticals. “We’re grateful that GoodRx’s platform has helped us reach more patients and caregivers to access a needle-free option so they can respond swiftly during a Type 1 allergic reaction.”

Consumers can access the savings on neffy at www.goodrx.com/neffy

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: GoodRx, Pharmacy

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

Digital Health Funding Q3 2025: Choppy Undercurrents Beneath a Steady Surface

Most-Read

Qualtrics Acquires Press Ganey Forsta for $6.75B to Create the Most Comprehensive AI Experience Platform

Qualtrics Acquires Press Ganey Forsta for $6.75B to Create the Most Comprehensive AI Experience Platform

Pfizer and Trump Administration Announce Landmark Agreement to Lower Drug Costs

Pfizer and Trump Administration Announce Landmark Agreement to Lower Drug Costs

KLAS Report: Epic's Native Ambient Speech Tool Reshapes Customer AI Strategies

KLAS Report: Epic’s Native Ambient Speech Tool Reshapes Customer AI Strategies

Epic Unveils MyChart Central and New APIs to Advance Interoperability at Open@Epic

Epic Outlines Roadmap for Next-Generation Data Sharing at Open@Epic

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

RevSpring to Acquire Kyruus Health, Creating a Unified Patient Experience

RevSpring to Acquire Kyruus Health, Creating a Unified Patient Experience

Oracle Confirms Layoffs in Kansas City

Oracle Confirms Layoffs in Kansas City

Philips Future Health Index 2025: AI and Digital Tech Can Help Solve Cardiac Care Crisis

Philips Future Health Index 2025: AI and Digital Tech Can Help Solve Cardiac Care Crisis

Optain Health Secures $26M to Advance AI-Powered Retinal Screening

Optain Health Secures $26M for AI-Powered Retinal Screening

Sutter Health and Epic Launch "Sutter Sync" to Optimize Remote Chronic Care

Sutter Health and Epic Launch “Sutter Sync” to Optimize Remote Chronic Care

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |